These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21703200)

  • 21. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
    Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
    N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
    Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
    Zein CO; Yerian LM; Gogate P; Lopez R; Kirwan JP; Feldstein AE; McCullough AJ
    Hepatology; 2011 Nov; 54(5):1610-9. PubMed ID: 21748765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
    Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
    Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
    Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
    Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
    Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
    Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review.
    Polyzos SA; Mantzoros CS
    Metabolism; 2016 Sep; 65(9):1297-306. PubMed ID: 27506737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
    Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Sponseller CA; Hampton K; Bacon BR
    J Hepatol; 2003 Apr; 38(4):434-40. PubMed ID: 12663234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Musso G; Cassader M; Rosina F; Gambino R
    Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
    Chavez-Tapia NC; Barrientos-Gutierrez T; Tellez-Avila FI; Sanchez-Avila F; Montano-Reyes MA; Uribe M
    World J Gastroenterol; 2006 Dec; 12(48):7826-31. PubMed ID: 17203528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis.
    Sridharan K; Sivaramakrishnan G; Sequeira RP; Elamin A
    Postgrad Med J; 2018 Oct; 94(1116):556-565. PubMed ID: 30341231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
    Han MAT; Altayar O; Hamdeh S; Takyar V; Rotman Y; Etzion O; Lefebvre E; Safadi R; Ratziu V; Prokop LJ; Murad MH; Noureddin M
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):616-629.e26. PubMed ID: 29913275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis.
    Singh S; Loke YK; Furberg CD
    Thorax; 2011 May; 66(5):383-8. PubMed ID: 21325145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.
    Zhu K; Kakkar R; Chahal D; Yoshida EM; Hussaini T
    World J Gastroenterol; 2023 Oct; 29(37):5327-5338. PubMed ID: 37899788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin sensitizers in nonalcoholic steatohepatitis.
    Harrison SA; Schenker S; Cusi K
    Hepatology; 2011 Apr; 53(4):1404-5; author reply 1405. PubMed ID: 21480350
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.